Welcome to our news page where you can find our latest media releases.
If you are a media professional, please get in touch with our communications team.
Latest news for Trade and Medical Media
Press releases
| DATE | Title | ||||
|---|---|---|---|---|---|
|
27 Apr
|
Mundipharma announces positive topline results from phase iii respect trial assessing ▼REZZAYO® (REZAFUNGIN) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients | VIEW |
| DATE | Title | ||||
|---|---|---|---|---|---|
|
24 APR
|
Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area | VIEW | |||
|
18 APR
|
Mundipharma and Vectura announce plans to reformulate flutiform® (fluticasone propionate/formoterol fumarate) pressurised metered- dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint | VIEW |
| DATE | Title | ||||
|---|---|---|---|---|---|
|
16 NOV
|
Napp announces acceptance of their Rezafungin Marketing Authorisation Application for the Treatment of Invasive Candidiasis to the UK Medicines and Healthcare Products Regulatory Agency | VIEW | |||
|
22 AUG
|
European Medicines Agency accepts rezafungin marketing authorisation application for the treatment of invasive candidiasis | VIEW | |||
|
25 APR
|
Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile | VIEW | |||
|
03 MAR
|
Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Invasive Candidiasis | VIEW |
| DATE | Title | ||||
|---|---|---|---|---|---|
|
14 DEC
|
Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis | VIEW | |||
| Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis | View | ||||
| Large-scale study shows oral hydroxychloroquine and povidone-iodine throat spray can reduce spread of Covid-19 in high transmission settings | view | ||||
| Orphan Drug Designation granted to rezafungin in EU | view | ||||
| Julie Dehaene-Puype and Erik Nordkamp appointed as new regional Commercial Officers for Mundipharma | View |
| DATE | Title | ||||
|---|---|---|---|---|---|
| Mundipharma ranked one of the 2020 Best Workplaces in Europe by Great Place to Work® | view | ||||
| European Commission approves extended Invokana® (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes seen in CREDENCE study | view | ||||
| Marc Princen appointed new Global CEO for Mundipharma | VIEW |
Media enquiries
Global Media Office
[email protected]
Mundipharma International Limited
Cambridge Science Park
Milton Road
Cambridge
CB4 0AB
Tel: +44 (0)1223 424211
Please note that the medicines mentioned may not be available in all countries. Additionally, currently approved indications and presentations may differ between countries. Please always ask a healthcare professional for advice regarding medicines and refer to individual countries for full product indication and local prescribing information.